Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph S Friedberg

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Molecular Carcinogenesis|March 23, 2022
Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotypeWarren Naselsky, Gautam Adhikary, Suruchi Shrestha, et al.
Annals of Thoracic Surgery Short Reports|January 10, 2025
Circumferential Pulmonary Ossification From Lung Extraskeletal Osteosarcoma With Mediastinal ShiftHannah R Calvelli, Louis F Chai, Jonathan A Nakata, et al.
Photochemistry and Photobiology|August 22, 2003
Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapySue S Yom, Theresa M Busch, Joseph S Friedberg, et al.
Molecular Cancer Research : MCR|September 1, 2023
Correction: The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell PhenotypeSivaveera Kandasamy, Gautam Adhikary, Ellen A Rorke, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 21, 2018
Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resectionVivek Verma, Christopher A Ahern, Christopher G Berlind, et al.
Molecular Cancer Research : MCR|November 17, 2019
The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell PhenotypeSivaveera Kandasamy, Gautam Adhikary, Ellen A Rorke, et al.
Journal of Thoracic Disease|February 2, 2012
Photodynamic therapy for the treatment of non-small cell lung cancerCharles B Simone, Joseph S Friedberg, Eli Glatstein, et al.
The Annals of Thoracic Surgery|October 22, 2019
Posterior Intercostal Lymph Nodes Double Recurrence and Death Risk in Malignant Pleural MesotheliomaJoseph S Friedberg, Charles B Simone, Melissa J Culligan, et al.
Oncotarget|October 24, 2018
Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formationGautam Adhikary, Daniel Grun, H Richard Alexander, et al.
The Annals of Thoracic Surgery|May 31, 2011
Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesotheliomaJoseph S Friedberg, Rosemarie Mick, Melissa Culligan, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Molecular Carcinogenesis|March 23, 2022
Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotypeWarren Naselsky, Gautam Adhikary, Suruchi Shrestha, et al.
Annals of Thoracic Surgery Short Reports|January 10, 2025
Circumferential Pulmonary Ossification From Lung Extraskeletal Osteosarcoma With Mediastinal ShiftHannah R Calvelli, Louis F Chai, Jonathan A Nakata, et al.
Photochemistry and Photobiology|August 22, 2003
Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapySue S Yom, Theresa M Busch, Joseph S Friedberg, et al.
Molecular Cancer Research : MCR|September 1, 2023
Correction: The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell PhenotypeSivaveera Kandasamy, Gautam Adhikary, Ellen A Rorke, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 21, 2018
Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resectionVivek Verma, Christopher A Ahern, Christopher G Berlind, et al.
Molecular Cancer Research : MCR|November 17, 2019
The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell PhenotypeSivaveera Kandasamy, Gautam Adhikary, Ellen A Rorke, et al.
Journal of Thoracic Disease|February 2, 2012
Photodynamic therapy for the treatment of non-small cell lung cancerCharles B Simone, Joseph S Friedberg, Eli Glatstein, et al.
The Annals of Thoracic Surgery|October 22, 2019
Posterior Intercostal Lymph Nodes Double Recurrence and Death Risk in Malignant Pleural MesotheliomaJoseph S Friedberg, Charles B Simone, Melissa J Culligan, et al.
Oncotarget|October 24, 2018
Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formationGautam Adhikary, Daniel Grun, H Richard Alexander, et al.
The Annals of Thoracic Surgery|May 31, 2011
Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesotheliomaJoseph S Friedberg, Rosemarie Mick, Melissa Culligan, et al.
Pageof 8